RxDoctor Payments Data

Gabriel Samuel Chua, MD

Family Medicine · Vallejo, CANPI 1265476428

Payments from drug & device makers

$2,629in general payments, 2019–2025

Across 191 payments — averaging $13.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$699
  • AbbVie$405
  • AstraZeneca$276
  • Lilly USA, LLC$228
  • Bayer$194
  • Merck$148
  • plus $678 from 13 others

What the payments were for

  • Food & beverage$2,60699%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,629 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$225,290
Medicare patients
538
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide123$180,881
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$83,708
JardianceEmpagliflozin60$83,214
OzempicSemaglutide69$75,054
EliquisApixaban70$74,042
JanuviaSitagliptin Phosphate34$45,939
XareltoRivaroxaban47$44,082
Breo ElliptaFluticasone/Vilanterol107$42,241
RybelsusSemaglutide23$35,902
MounjaroTirzepatide31$32,784
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$24,163
FarxigaDapagliflozin Propanediol25$23,383
OxycontinOxycodone Hcl11$18,299
JanumetSitagliptin Phos/Metformin Hcl11$18,268
Tresiba Flextouch U-100Insulin Degludec22$14,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$228$213,665154 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$145$142,964257 claims
Novo NordiskOzempic, Rybelsus$699$110,95692 claims
Boehringer IngelheimJardiance, Combivent Respimat$46$91,43477 claims
PfizerEliquis, Lipitor$84$80,37981 claims
MerckJanuvia, Janumet$148$64,20745 claims
AstraZenecaFarxiga$276$23,38325 claims
AbbVieLinzess$405$12,10617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Vallejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →